A prospective, multicenter phase 2 trial evaluated the safety of neoadjuvant radiation plus immunotherapy before radical cystectomy for bladder cancer.

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced the publication of the PREDICT-DNA study in the Journal of Clinical Oncology. The article, "The ...

A phase 2/3 trial evaluates the efficacy and safety of neoadjuvant therapy with gemcitabine-oxaliplatin, lenvatinib, and ...

ENHERTU Granted Priority Review in the U.S. as Post-Neoadjuvant Treatment for Patients with HER2 Positive Early Breast Cancer ...

Priority review and Project Orbis evaluation advance potential post-neoadjuvant use of trastuzumab deruxtecan for high-risk HER2-positive early breast cancer with residual disease after neoadjuvant ...

Neoadjuvant chemoimmunotherapy may beat immunotherapy alone when it comes to pathologic response, but its impact on survival remains to be seen.

The firms submitted data from the Phase III DESTINY-Breast05 trial comparing Enhertu to Roche's antibody-drug conjugate Kadcyla.

FDA Priority Review was granted for trastuzumab deruxtecan in post-neoadjuvant HER2-positive early breast cancer with residual invasive disease, with a regulatory decision anticipated in Q3 2026.

In this article, we will look at the 12 Most Profitable Blue Chip Stocks to Invest In Now. On March 12, Stephen Parker, JPMorgan Private Bank co-head of global investment strategy, appeared on CNBC’s ...

Explore the latest colorectal cancer treatment advances, from precision oncology and immunotherapy to ADCs, bispecifics, and ...

In this article, we will discuss the Goldman Sachs Healthcare Stocks: Top 10 Stock Picks. The healthcare sector, long seen as ...

Data show T-DXd improves invasive disease-free survival and reduces the risk of distant recurrence in early HER2-positive breast cancer.